Transplant recipients
Conditions
Interventions
Patients are treated with tacrolimus, everolimus, sirolimus or ciclosporin, in the dose prescribed by their treating physician. In addition to the standard venous samples, DBS samples will be collecte
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: - Aged 18 and over - Able to understand written information and able to give informed consent - Treated with tacrolimus, everolimus, sirolimus and/or ciclosporin - Able and willing to undergo a finger prick for dried blood spot sampling - Able and willing to fill in a questionnaire
Exclusion criteria
Exclusion criteria: - Unable to draw blood samples for study purposes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimizing the correction factor needed and clinically validating a DBS method for tacrolimus, everolimus, sirolimus, ciclosporin and creatinine. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Analyzing the differences in the measured concentrations in the dried blood spot made with blood obtained from venous sampling and capillary sampling. - Evaluating the need of a correction factor when measuring the hematocrit in the DBS samples - Analyzing the difference between the drug concentration in the microtainer and filtrate card, to investigate the influence of the filtrate card on the drug concentration | — |
Contacts
Public ContactBrenda de Winter
Erasmus Medical Center
Outcome results
None listed